PlainRecalls
FDA Drug Moderate Class II Ongoing

Carvedilol Tablets, USP, 25 mg, Rx only, a)500 Tablets, NDC 68462-165-05; b) 100 Tablets, NDC 68462-165-01, Manufactured for Glenmark Pharmaceuticals, NJ.

Reported: February 12, 2025 Initiated: January 22, 2025 #D-0215-2025

Product Description

Carvedilol Tablets, USP, 25 mg, Rx only, a)500 Tablets, NDC 68462-165-05; b) 100 Tablets, NDC 68462-165-01, Manufactured for Glenmark Pharmaceuticals, NJ.

Reason for Recall

CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.

Details

Distribution
Nationwide in the U.S
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Carvedilol Tablets, USP, 25 mg, Rx only, a)500 Tablets, NDC 68462-165-05; b) 100 Tablets, NDC 68462-165-01, Manufactured for Glenmark Pharmaceuticals, NJ.. Recalled by Glenmark Pharmaceuticals Inc., USA.
Why was this product recalled?
CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 12, 2025. Severity: Moderate. Recall number: D-0215-2025.